CompletedNCT00915512
Long-term treatment response and safety of paliperidone for schizophrenia
About this title
Read the official source — NCT00915512Medication studyAges 18–65Türkiye
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Adana and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMay 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 84
- Sponsor
- Janssen-Cilag Turkey
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Türkiye
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00915512
- Official title
Show the full official title
An Open-label, Single-arm, Multicenter, Phase IV Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-release Paliperidone in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Adana, Türkiye · Ankara, Türkiye · Antalya, Türkiye
5 more locations
- Bursa, Türkiye
- Istanbul, Türkiye
- Manisa, Türkiye
- Samsun, Türkiye
- Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag Turkey.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone extended-release (ER).
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
